Ignite Creation Date:
2024-07-17 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06482892
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-06-20
Brief Title:
A Single Arm Clinical Study Evaluating the Safety Tolerability and Efficacy of Multiple Intravenous Administration of TP03HN106 in Patients With Critical Limb Ischemia
Sponsor:
Talengen Institute of Life Sciences Shenzhen PR China
Organization:
Talengen Institute of Life Sciences Shenzhen PR China
Study Overview
Official Title:
A Single Arm Clinical Study Evaluating the Safety Tolerability and Efficacy of Multiple Intravenous Administration of TP03HN106 in Patients With Critical Limb Ischemia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Critical limb ischemia CLI is the most severe ischemic stage in peripheral arterial disease PAD of the lower limbs characterized by decreased walking ability resting pain lasting for more than 2 weeks ulcers and gangrene which seriously affect the quality of life of patients Some patients may even face amputation or death Thrombosis is an important pathological feature of CLI TP03HN106 can promote thrombolysis thus having a therapeutic effect on CLI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None